NEW YORK (GenomeWeb News) – The Foundation for the National Institutes of Health on Thursday announced that the I-SPY 2 Trial has graduated the first two drugs from its multidrug standing platform trial.

The two drugs are veliparib, developed by AbbVie, and neratinib, developed by Puma Biotechnology. Both are for breast cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.

By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.

Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.

In Nature this week: a Danish reference genome, and more.

Sep
21
Sponsored by
Roche

This webinar will demonstrate a new approach that combines precise FFPE tumor isolation with extraction-free DNA/RNA library preparation to minimize material losses and reduce the amount of tissue input required for NGS analysis.